Chemed Co. (CHE) Holdings Trimmed by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in Chemed Co. (NYSE:CHE) by 8.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 3,966 shares of the company’s stock after selling 387 shares during the period. SG Americas Securities LLC’s holdings in Chemed were worth $1,267,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Laurion Capital Management LP purchased a new position in shares of Chemed in the second quarter worth about $492,000. Marshall Wace LLP purchased a new position in shares of Chemed in the second quarter worth about $1,433,000. First Trust Advisors LP raised its stake in shares of Chemed by 370.3% in the third quarter. First Trust Advisors LP now owns 81,596 shares of the company’s stock worth $26,076,000 after purchasing an additional 64,248 shares during the last quarter. Virginia Retirement Systems ET AL raised its stake in shares of Chemed by 18.1% in the third quarter. Virginia Retirement Systems ET AL now owns 91,400 shares of the company’s stock worth $29,210,000 after purchasing an additional 14,000 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Chemed by 2.3% in the third quarter. US Bancorp DE now owns 16,755 shares of the company’s stock worth $5,355,000 after purchasing an additional 376 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Shares of NYSE:CHE opened at $302.95 on Friday. Chemed Co. has a 52-week low of $234.00 and a 52-week high of $335.99. The stock has a market capitalization of $4.90 billion, a PE ratio of 26.94, a PEG ratio of 2.68 and a beta of 1.18. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.14 and a quick ratio of 1.11.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, beating the consensus estimate of $2.80 by $0.27. The company had revenue of $444.15 million during the quarter, compared to analysts’ expectations of $445.16 million. Chemed had a return on equity of 35.13% and a net margin of 11.73%. Chemed’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the business earned $2.15 earnings per share. As a group, equities analysts predict that Chemed Co. will post 11.41 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Monday, November 12th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend was Thursday, November 8th. Chemed’s dividend payout ratio is currently 22.39%.

Several research analysts have recently issued reports on CHE shares. Zacks Investment Research restated a “buy” rating and issued a $342.00 price objective on shares of Chemed in a research note on Monday, November 12th. Bank of America started coverage on Chemed in a research note on Friday, October 12th. They issued a “buy” rating and a $390.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $332.00.

In related news, Director Donald E. Saunders sold 300 shares of Chemed stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $308.74, for a total transaction of $92,622.00. Following the completion of the transaction, the director now directly owns 8,251 shares in the company, valued at $2,547,413.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kevin J. Mcnamara sold 7,000 shares of Chemed stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $305.98, for a total value of $2,141,860.00. Following the transaction, the insider now owns 141,293 shares of the company’s stock, valued at $43,232,832.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,953 shares of company stock valued at $7,678,463. 4.90% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “Chemed Co. (CHE) Holdings Trimmed by SG Americas Securities LLC” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/12/08/chemed-co-che-holdings-trimmed-by-sg-americas-securities-llc.html.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Recommended Story: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply